Analysts Offer Predictions for Biomea Fusion Q3 Earnings

Biomea Fusion, Inc. (NASDAQ:BMEA) – Research analysts at Brookline Capital Markets issued their Q3 2026 earnings per share (EPS) estimates for Biomea Fusion in a research report issued on Wednesday, October 7th. Brookline Capital Markets analyst K. Raja forecasts that the company will earn ($0.18) per share for the quarter. Brookline Capital Markets currently has a “Buy” rating on the stock. The consensus estimate for Biomea Fusion’s current full-year earnings is ($0.73) per share. Brookline Capital Markets also issued estimates for Biomea Fusion’s Q4 2026 earnings at ($0.18) EPS, FY2026 earnings at ($0.65) EPS, FY2027 earnings at ($0.67) EPS, FY2028 earnings at ($0.77) EPS, FY2029 earnings at ($0.80) EPS and FY2030 earnings at ($0.84) EPS.

Biomea Fusion (NASDAQ:BMEA) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.10.

BMEA has been the topic of several other research reports. Wall Street Zen raised shares of Biomea Fusion from a “sell” rating to a “hold” rating in a report on Monday. Citigroup restated a “market outperform” rating on shares of Biomea Fusion in a research report on Wednesday, September 30th. HC Wainwright restated a “buy” rating on shares of Biomea Fusion in a research note on Monday, August 24th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Biomea Fusion in a research note on Monday, September 28th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $9.00.

Biomea Fusion Price Performance

NASDAQ BMEA opened at $1.37 on Friday. The company’s 50 day simple moving average is $1.52 and its two-hundred day simple moving average is $1.46. Biomea Fusion has a 1 year low of $0.87 and a 1 year high of $2.24. The stock has a market capitalization of $99.30 million, a PE ratio of -4.72 and a beta of -0.28.

Hedge Funds Weigh In On Biomea Fusion

A number of hedge funds and other institutional investors have recently modified their holdings of BMEA. Renaissance Technologies LLC increased its position in shares of Biomea Fusion by 174.3% during the 1st quarter. Renaissance Technologies LLC now owns 1,312,798 shares of the company’s stock valued at $2,009,000 after purchasing an additional 834,179 shares during the last quarter. BlackRock Inc. bought a new stake in Biomea Fusion in the 2nd quarter worth approximately $1,052,000. GSA Capital Partners LLP bought a new stake in Biomea Fusion in the 2nd quarter worth approximately $318,000. ADAR1 Capital Management LLC purchased a new stake in Biomea Fusion in the second quarter worth approximately $64,000. Finally, Rathbones Group PLC purchased a new stake in Biomea Fusion in the first quarter worth approximately $57,000. 96.72% of the stock is currently owned by hedge funds and other institutional investors.

Biomea Fusion Company Profile

Biomea Fusion, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for serious diseases with significant unmet medical needs. The company’s research platform is centered on covalent chemistry, an approach designed to create potentially durable interactions between medicines and their biological targets.

Biomea’s lead investigational product is icovamenib, formerly known as BMF-219, an oral covalent menin inhibitor. The company has evaluated icovamenib in oncology indications, including certain blood cancers, and is also investigating its potential in metabolic diseases such as diabetes.